Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Fludarabine; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 16 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 22 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.